Pityriasis Rosea

Definition

Epidemiology

• Worldwide distribution; all races affected
• Incidence: ~160 cases per 100,000 person-years (US data); 0.64 per 100 dermatologic patients globally
• Peak age: 10 to 35 years (cases reported from 3 months to 83 years)
• Slight female predominance (F:M ratio ~1.39:1)
• Possible seasonal clustering (some studies show more cases in spring and autumn)
• Relapse is uncommon: 1.8-3.7%

Etiology and Pathogenesis

• HHV-7 DNA has been found in lesional skin, peripheral blood mononuclear cells, and plasma of PR patients, but not controls
• HHV-7 may trigger reactivation of latent HHV-6
• Both viruses are virtually universal in adults (HHV-6 seropositivity 80-100%; HHV-7 >85%), making causality difficult to prove definitively
• The eruption may represent either primary infection or reactivation leading to viremia
• HHV-2 and hepatitis C virus have also been implicated in isolated cases

Note: Case clustering, possible seasonal variation, and the resemblance to other viral exanthems all support an infectious cause.

Clinical Features

The Herald Patch (Primary Lesion)

• Present in 50-90% of patients
• A single, 3-5 cm oval erythematous scaly plaque on the trunk (rarely an extremity)
• Has a collarette of fine scale just inside the periphery (scale points inward)
• Precedes the generalized eruption by ~1-2 weeks in adults, ~4 weeks in children
• Commonly mistaken for tinea corporis because it appears as an isolated scaling plaque

Secondary Eruption

• Follows the herald patch by 1-2 weeks
• Smaller (0.5-1.5 cm) salmon-pink oval patches and plaques, mainly on the trunk and proximal extremities
• Long axis of lesions oriented parallel to skin cleavage lines (Langer's lines)
• On the back, this creates the classic "Christmas tree" or "fir tree" pattern
• Collarette of scale with the open (free) edge pointing inward - the "hanging curtain sign"
• Palms and soles are typically spared
• Face is usually spared (exception: children with darker skin)

Systemic Symptoms

• Mild pruritus (can be moderate-severe in some)
• Mild prodromal flu-like symptoms may precede the eruption in some patients
• These symptoms are transient

Atypical Variants

In darker-skinned patients, lesions often resolve leaving post-inflammatory hypopigmentation.

Histopathology

• Epidermal changes: Mounded parakeratosis with "liftoff," mild acanthosis, spongiosis
• Dermal changes: Superficial perivascular lymphocytic infiltrate, red blood cell extravasation (erythrocyte extravasation is a hallmark)
• Inflammatory infiltrate: predominantly lymphocytes, with neutrophils, histiocytes; occasional eosinophils
• Herald patch may show slightly deeper infiltrate and more acanthosis compared to secondary lesions
• Biopsy is non-specific but can help exclude other diagnoses

Diagnosis

1. Herald patch
2. Christmas tree distribution on trunk
3. Oval lesions along skin cleavage lines
4. Collarette of scale (free edge inward)
5. Self-limited, 4-8 week course

Differential Diagnosis

Clinical pearl: Always rule out secondary syphilis, especially when palms and soles are involved - order a serology (RPR or VDRL).

Drug-Induced PR-like Eruptions

• ACE inhibitors (captopril, lisinopril)
• Imatinib mesylate
• Interferons
• Gold, bismuth, arsenicals
• Clonidine, barbiturates
• Ketotifen
• Adalimumab, lithium, acyclovir, ergotamine

Special Situation: PR in Pregnancy

• Associated with adverse pregnancy outcomes, particularly in the first trimester
• In PR onset before 15 weeks gestation: ~62% resulted in miscarriage in one study
• Can also be associated with premature delivery and neonatal hypotonia/hyporeactivity
• Women who develop PR during pregnancy, especially in the first trimester, should be monitored closely

Treatment

Acyclovir is considered when: widespread eruption, severe pruritus, significant systemic symptoms, or pregnancy (to potentially reduce adverse outcomes). It is most beneficial if started early in the course.

Prognosis and Complications

• Complete resolution in 6-8 weeks in most patients (range 4-16 weeks)
• No long-term complications in healthy individuals
• Can cause anxiety and depression in ~30% of cases due to uncertainty about the diagnosis
• Recurrence is uncommon (1.8-3.7%)
• Post-inflammatory hyperpigmentation or hypopigmentation may persist, especially in darker skin tones

Summary Table

• Fitzpatrick's Dermatology (Chap. 31), pp. 550-554
• Andrews' Diseases of the Skin, p. 1915
• Goldman-Cecil Medicine, p. 4280
• Tintinalli's Emergency Medicine, p. 1679

HCV Transmission Risk After This Needlestick: Breakdown

The Key Factor: The Patient's HCV Status

1. Completed treatment for Hepatitis C
2. Tests every 3 months
3. Is currently HCV RNA negative

Risk Calculation

Scenario A: Patient is genuinely cured (SVR, HCV RNA negative)

Scenario B: Patient's test results are accurate but you are uncertain

• Average: 1.8% per injury (range 0% to 7%)
• This is already quite low compared to HBV (~30%) or even HIV (~0.3%)

Factors that would increase risk (none of which apply here ideally):

What Should the Doctor Do Right Now?

Immediate (within minutes):

• Wash the wound with soap and water for at least 15 minutes
• Do NOT squeeze or suck the wound

Within 24-48 hours - Report and test:

1. Report to occupational health (mandatory in most institutions)
2. Test the source patient - confirm anti-HCV and ideally HCV RNA (don't just take her word for it - get documented lab results)
3. Baseline blood work on the doctor: anti-HCV antibody + ALT/AST today

Follow-up testing for the doctor:

• Repeat anti-HCV + ALT at 4-6 months post-exposure
• If desired (for earlier detection): HCV RNA at 4-6 weeks post-exposure (RNA becomes detectable before antibodies)
• All positive anti-HCV results must be confirmed with nucleic acid testing (HCV RNA)

Post-Exposure Prophylaxis (PEP):

• No PEP exists for HCV - unlike HIV, there is no recommended post-exposure antiviral prophylaxis for HCV
• Immunoglobulin is also not recommended (no evidence of efficacy)
• If infection is documented later, treat immediately with highly effective direct-acting antivirals (DAAs) - cure rates >95%

Bottom Line

• Yamada's Textbook of Gastroenterology, 7th ed., p. 1908

Does "Face Mesotherapy" Change the Risk?

What actually determines HCV transmission risk:

What Face Mesotherapy Does Tell Us (Practically)

• Facial mesotherapy typically uses 30G or 31G insulin syringes with very short needles (4-6 mm)
• These are intradermal/subcutaneous injections - very superficial
• The blood volume retained in the needle dead space is minimal (insulin syringes are designed as low dead-space devices)
• The fingertip prick from such a needle carries less inoculum than a phlebotomy needle or IV cannula would

Reassurance Summary

Risk to the doctor = effectively zero, because the patient is cured of HCV (SVR, RNA negative). The needle gauge, injection site, and small blood volume all further reduce any residual theoretical concern.

1. Wash the wound with soap and water
2. Report to occupational health
3. Get the source patient's HCV RNA documented from an actual lab result (not just verbal history)
4. Get baseline anti-HCV + ALT, and repeat at 4-6 months

Foreign Body Aspiration Masquerading as Asthma - Full Teaching Case

The Clinical Trap in This Case

Step 1: Reframe the Diagnosis

This child has three features pointing away from simple asthma: age 4, unilateral findings, and bronchodilator failure.

Why the Right Side?

• It is wider in diameter
• It has a steeper, more vertical course from the trachea (more in line with the tracheal axis)
• The carina is slightly to the left, directing objects rightward

The Two Investigations to Order

1. Chest X-Ray (CXR) - PA + Lateral + Expiratory/Decubitus Views

A normal CXR does NOT rule out FBA.

• Plain films are normal in >25% of bronchial FBs
• >75% of FBs in children <3 years are radiolucent (organic material: peanuts, seeds, carrots)
• The absence of a radiopaque object means nothing

• On inspiration, both lungs expand - may look normal
• On expiration, the obstructed lung cannot deflate - remains hyperinflated while the normal lung deflates
• The mediastinum shifts AWAY from the obstructed side on expiration

• In a normal lung, the dependent lung compresses (deflates) when the child lies on that side
• With an FB causing air trapping, the affected lung stays hyperinflated regardless of position
• However: bilateral decubitus films increase false positives without increasing true positives - use judiciously

2. Arterial Blood Gas (ABG)

The "calm child" trap: A child in severe respiratory distress who suddenly becomes quiet is NOT getting better - they may be developing CO2 narcosis. An ABG here is life-saving.

The Two Obstruction Patterns (Expanded)

FOREIGN BODY IN RIGHT BRONCHUS
         |
    ─────┴─────
    |           |
PARTIAL      COMPLETE
OBSTRUCTION  OBSTRUCTION
    |           |
Ball-valve    Absorbed air
mechanism     distal to FB
    |           |
AIR TRAPPING  ATELECTASIS
HYPERINFLATION COLLAPSE
    |           |
Right lung     Right lung
BIGGER than    SMALLER than
left on CXR    left on CXR
Mediastinum    Mediastinum
shifts LEFT    shifts RIGHT

The Diagnostic Pathway

Unilateral wheeze / reduced air entry not responding to bronchodilator
                          ↓
                    SUSPECT FBA
                          ↓
              Is child stable? ────────── NO → Emergency airway maneuvers
                          |                    (BLS, laryngoscopy, intubate)
                         YES
                          ↓
                CXR (PA + lateral)
                + Expiratory film
                          ↓
              ┌───────────┴──────────────┐
         Abnormal                     Normal
    (hyperinflation,              (but high clinical
     atelectasis, FB)              suspicion remains)
              ↓                         ↓
       CT CHEST               FLEXIBLE BRONCHOSCOPY
    (~100% sensitivity)        (diagnostic + therapeutic)
              ↓
    If confirmed → RIGID BRONCHOSCOPY for removal

Management Decision Tree

Immediate (if child is in distress):

• Oxygen - high flow
• DO NOT give more bronchodilators (will not help; may waste time)
• DO NOT attempt sedation or RSI if maintaining airway - partial obstruction becomes complete with loss of tone

If responsive with partial obstruction (this child's likely scenario):

• Encourage coughing
• Supplemental oxygen
• Do NOT do back blows/Heimlich - these are for acute complete obstruction
• Arrange urgent bronchoscopy

Definitive removal:

• Allows simultaneous ventilation through the scope
• Better control and suction
• Can remove large objects that flexible scope cannot grasp
• Preferred in any age <12 years or with respiratory compromise

Adjuncts and Post-Removal Care

• Corticosteroids: reduce edema and granulation tissue around the FB (especially in delayed presentations) - facilitates removal
• Antibiotics: post-obstructive pneumonia is common, especially if FB was present for days
• Evaluate for recurrence: if FB was in right bronchus and not recovered, it can be coughed up and cause sudden upper airway obstruction later

Complications of Missed/Delayed FBA

This is why FBA must be on your differential in ANY child with unilateral wheeze or bronchodilator-unresponsive wheeze - even if they carry a diagnosis of asthma. The two can coexist.

Summary: Key Teaching Points

1. Unilateral findings = think FBA, not asthma, even in a known asthmatic
2. Right bronchus is involved more often due to its steeper vertical course
3. CXR is the first-line investigation - look for indirect signs (hyperinflation, atelectasis, mediastinal shift); a normal CXR does NOT exclude FBA
4. Expiratory film is the most helpful CXR view - reveals air trapping on the obstructed side
5. ABG is indicated here because bronchodilators failed - you must assess ventilatory status and exclude impending respiratory failure
6. A "normalizing" PaCO2 in a tachypneic distressed child is a danger sign
7. Bronchoscopy is gold standard - both diagnostic and therapeutic; use rigid scope in children
8. Do not paralyze a child maintaining their airway - you may convert partial to complete obstruction

• Rosen's Emergency Medicine, p. 3175
• Tintinalli's Emergency Medicine, p. 836

PE Confirmed in CKD - Next Appropriate Investigation: VQ Scan vs D-Dimer

First: Read the Question Carefully

Part 1: Why the Answer is VQ Scan (Not D-Dimer)

Why D-Dimer is Wrong Here

• Renal failure causes impaired fibrinolysis
• Inflammatory state of CKD raises D-Dimer
• CKD patients often have comorbidities (infection, malignancy, immobility) that all elevate D-Dimer independently

A positive D-Dimer in CKD is essentially meaningless. A negative D-Dimer is the only useful result - but again, PE is already confirmed, so this is a moot point.

Why VQ Scan is the Answer

PE is confirmed clinically/by initial workup, but CTPA (CT Pulmonary Angiography) cannot be used because the patient has CKD.

• Acute contrast-induced nephropathy (CIN)
• Accelerating progression to end-stage renal disease
• In advanced CKD (GFR <30), this is a significant risk

• Uses radiolabelled tracers (technetium-99m) - NOT nephrotoxic
• No contrast agent required
• Safe in renal failure
• Can confirm/characterize PE without harming kidneys

The Full Diagnostic Logic for PE (So You Understand Where VQ Fits)

Suspected PE
     ↓
Wells Score / Clinical Probability
     ↓
     ┌─────────────────────────────┐
  LOW/INTERMEDIATE               HIGH
  PROBABILITY                 PROBABILITY
     ↓                            ↓
  D-DIMER                    Image DIRECTLY
  (if negative → PE excluded)
  (if positive → Image)
     ↓
  ┌──────────────────────────────────────────┐
  |           IMAGING OPTIONS               |
  ├──────────────────────────────────────────┤
  | Normal renal function → CTPA (1st line) |
  | CKD / contrast allergy → VQ SCAN        |
  | Pregnancy → VQ SCAN (normal CXR) or     |
  |             CTPA (abnormal CXR)         |
  | Inconclusive → Pulmonary angiography    |
  |               (gold standard, invasive) |
  └──────────────────────────────────────────┘

CTPA vs VQ Scan - Head to Head

VQ Scan - How It Works and How to Read It

1. Ventilation (V): Patient inhales radioactive gas (e.g., Xenon-133 or Tc-99m DTPA aerosol) - shows where air goes
2. Perfusion (Q): IV injection of Tc-99m MAA particles - shows where blood goes

PIOPED Criteria for Interpretation:

Important: In patients with underlying lung disease (COPD, pneumonia), VQ scans are more often intermediate/indeterminate - reducing their usefulness. This is when CTPA (if kidneys allow) or pulmonary angiography is needed.

Part 2: Management in CKD - The Critical Changes

The Central Problem with CKD and Anticoagulation

Initial Anticoagulation (First 5-10 days)

Key teaching point: UFH is the anticoagulant of choice for initial treatment of PE in CKD/renal failure. It is also preferred if thrombolysis or embolectomy is being planned (easy reversal).

Long-Term Anticoagulation (Up to 3 months and beyond)

• Mild-moderate CKD (GFR 30-60): DOACs with caution; avoid dabigatran
• Severe CKD (GFR <30): UFH acutely → transition to warfarin for long-term
• Dialysis: Warfarin (though evidence is limited and controversial; some guidelines now suggest no anticoagulation for provoked PE in dialysis patients due to bleeding risk)

Severity Stratification - Why It Matters for Management

CONFIRMED PE
      ↓
Check hemodynamics + RV function + troponin
      ↓
┌─────────────────────────────────────────────────┐
│ MASSIVE PE (SBP <90 or drop ≥40 mmHg >15 min)  │
│ → UFH immediately                               │
│ → Thrombolysis (if no contraindication)         │
│   [CKD is NOT a contraindication to tPA]        │
│ → Surgical/catheter embolectomy if thrombolysis │
│   fails or is contraindicated                   │
├─────────────────────────────────────────────────┤
│ SUBMASSIVE PE (stable BP + RV dysfunction       │
│ or elevated troponin)                           │
│ → UFH (preferred in CKD)                        │
│ → Consider thrombolysis if deteriorating        │
│ → Monitor closely                               │
├─────────────────────────────────────────────────┤
│ NONMASSIVE PE (stable, no RV dysfunction)       │
│ → Anticoagulation alone                         │
│ → UFH initially in CKD                          │
│ → Transition to warfarin long-term in severe CKD│
└─────────────────────────────────────────────────┘

Summary: The Entire Concept on One Page

• Grainger & Allison's Diagnostic Radiology
• Fishman's Pulmonary Diseases and Disorders
• Murray & Nadel's Textbook of Respiratory Medicine

Pancoast Tumour (Superior Sulcus Tumour) - Complete Teaching

The Clinical Scenario Decoded

Anatomy First - Why Pancoast Tumour Does What It Does

APEX OF LUNG (Superior Sulcus)
        ↓
  Tumour grows upward and outward
        ↓
  Invades adjacent structures:

┌──────────────────────────────────────────────────────┐
│ Structure Invaded         → Clinical Feature          │
├──────────────────────────────────────────────────────┤
│ Lower brachial plexus     → Arm/hand pain + wasting  │
│ (C8, T1, T2 roots)        → Ulnar distribution pain  │
│                           → Small muscle atrophy     │
├──────────────────────────────────────────────────────┤
│ Paravertebral sympathetic → Horner's syndrome        │
│ chain + stellate ganglion │ (Ptosis, Miosis,         │
│                           │  Anhidrosis, Enophthalmos)│
├──────────────────────────────────────────────────────┤
│ Parietal pleura + ribs    → Shoulder/chest wall pain │
│ (1st, 2nd, 3rd ribs)      │                          │
├──────────────────────────────────────────────────────┤
│ Subclavian vessels        → Vascular compromise      │
├──────────────────────────────────────────────────────┤
│ Vertebral bodies          → Spinal cord compression  │
│ (late)                    → Paraplegia (rare)        │
└──────────────────────────────────────────────────────┘

Pancoast Syndrome - The Full Picture

1. Shoulder and arm pain - along C8/T1/T2 distribution - often radiates to axilla and down the ulnar border of arm (ring and little fingers)
2. Weakness and atrophy of intrinsic hand muscles - ulnar nerve distribution (most hand intrinsics = C8/T1)
3. Horner's syndrome - ipsilateral ptosis, miosis, anhidrosis (±enophthalmos)

Important: Pancoast syndrome is present in only ~1/3 of patients with superior sulcus tumours. The rest may have the tumour without all three components.

• Cough (pulmonary primary)
• Small muscle wasting (lower brachial plexus T1 involvement)

What Type of Tumour is a Pancoast Tumour?

• Mostly NSCLC (non-small cell lung cancer) - squamous cell or adenocarcinoma
• Rarely SCLC, carcinoid, or metastatic disease
• Occasionally non-malignant (infections, lymphoma, mesothelioma)
• Defined by location (superior sulcus), not histology
• Chest wall involvement must be at or above the first rib - below the 2nd rib it is NOT a Pancoast tumour

The Investigation Question - X-Ray vs NCS vs CT vs MRI

Investigation 1: Chest X-Ray

• Apical opacity / soft tissue mass at lung apex
• Rib destruction (1st, 2nd ribs - pathognomonic)
• Pleural thickening at apex
• Atelectasis or consolidation if bronchus is involved
• Asymmetry of apical soft tissues

• The lung apex is a blind spot on standard PA CXR - overlying clavicle, ribs and soft tissues obscure it
• A normal CXR does NOT rule out Pancoast tumour
• Some tumours are only identified on CT

If clinical suspicion is high but CXR is negative or equivocal → go straight to CT / MRI.

Investigation 2: NCS (Nerve Conduction Study) - Why It Does NOT Find the Cause

• Electrical conduction along peripheral nerves
• Can confirm that the ulnar nerve (or other nerves) is NOT conducting normally
• Can localise the site of a nerve lesion to a general region (e.g., "proximal" vs "distal")

• NCS evaluates the nerve distal to the point of compression
• In Pancoast, the damage is at the nerve ROOT level (C8/T1) - the most proximal part of the brachial plexus, essentially where the root exits the spinal cord / enters the plexus
• NCS cannot image the root compression; it can only show downstream effects
• More importantly: NCS tells you THAT there is nerve damage but NOT WHY or WHERE the compressing lesion is
• It cannot see a tumour, cannot see bony destruction, cannot see pleural invasion

• Confirms neurogenic pattern (denervation, reduced motor unit potentials)
• Helps differentiate from cervical spondylosis, carpal tunnel, or peripheral neuropathy
• Localises to lower trunk brachial plexus (C8/T1) level
• Useful to EXCLUDE other causes of hand wasting (e.g., MND, ulnar neuropathy at elbow)

NCS is supportive - it tells you the nerve is damaged. It does NOT show you the tumour causing it. You still need imaging.

Investigation 3: CT Chest

• The tumour mass at the apex
• Rib destruction (1st, 2nd ribs)
• Extent of chest wall invasion
• Mediastinal lymph node involvement
• Other pulmonary nodules (metastases/synchronous primaries)
• Pleural involvement

• CT is excellent for parenchymal and bony structures
• CT is inferior for soft tissue planes - especially:
  • Brachial plexus invasion (nerves are not well-seen on CT)
  • Subclavian vessel involvement
  • Extent of plexus involvement (which roots? how far?)
  • Subpleural fat plane involvement
  • Spinal cord / foraminal extension

CT cannot tell you reliably if the brachial plexus is invaded or how far - and this is critical for surgical planning.

Investigation 4: MRI - The Best Investigation

"MRI of the chest is considered to be superior for evaluating patients with superior sulcus tumors because of better assessment of invasion through the pleura and subpleural fat, better evaluation of plexus involvement, and better definition of subclavian vessel involvement."

• T1: Tumour vs fat planes (fat = bright, tumour = dark = invasion if fat plane lost)
• T2: Oedema, fluid, nerve signal
• Coronal and sagittal planes: Critical - shows the relationship of tumour to brachial plexus roots from above
• MR Angiography: Best assessment of subclavian vessel invasion specifically

1. Is the lower brachial plexus (C8, T1) invaded? - determines resectability
2. Is the subclavian artery/vein involved? - determines if vascular resection is needed
3. Is there foraminal or spinal cord extension? - determines if neurosurgical input needed
4. Exactly which nerve roots are involved? - predicts post-operative functional deficits

The Diagnostic Pathway - Summarised

Cough + Small muscle wasting (hand) + Shoulder pain
                    ↓
         SUSPECT PANCOAST TUMOUR
                    ↓
         CHEST X-RAY (PA + Apical lordotic view)
                    ↓
      ┌─────────────┴──────────────┐
   Abnormal                    Normal but
   (apical mass,                high suspicion
   rib destruction)                  ↓
         ↓                      Still proceed
    CT CHEST                    to CT/MRI
    (confirms mass,
     extent, nodes,
     bony destruction)
         ↓
    MRI CHEST (BEST)
    (brachial plexus invasion,
     subclavian vessels,
     spinal canal,
     subpleural fat planes)
         ↓
    Tissue Diagnosis
    ┌──────────────────────────────┐
    │ Bronchoscopy (~50% yield)   │
    │ CT-guided TTNA (>90% yield) │
    │ EBUS-FNA for mediastinal LN │
    └──────────────────────────────┘
         ↓
    Staging + Mediastinoscopy
    (exclude N2 disease before
     surgery - if N2+, surgery
     not beneficial)

Why the Sequence Matters for Exams

Management Overview

Resectable (T3N0M0 or T3N1M0, no vascular/spinal involvement):

1. Induction chemoradiotherapy (cisplatin + etoposide + 45 Gy radiation) x 2 cycles
2. Surgical resection - en bloc lobectomy + chest wall resection (ribs 1-3) + lower brachial plexus root ± stellate ganglion
3. 5-year survival with complete resection: ~54%

Unresectable (T4: subclavian artery, vertebral body, spinal cord, or N2/N3 nodes):

• Definitive chemoradiotherapy
• Palliative intent

Poor prognostic factors:

• N2 nodal involvement
• Vertebral body or supraclavicular involvement
• Incomplete resection
• Weight loss

Summary Table

• Murray & Nadel's Textbook of Respiratory Medicine
• Schwartz's Principles of Surgery, 11th ed.
• Robbins & Kumar Basic Pathology
• Gray's Anatomy for Students

Contraception in a Breastfeeding Woman Who Wants to Conceive in 12 Months

The Clinical Problem - Two Competing Goals

1. Contraception NOW - she is breastfeeding and does not want pregnancy immediately
2. Fertility WITHIN 12 MONTHS - she wants to conceive again soon

• Is safe while breastfeeding (does not reduce milk supply or harm infant)
• Has a rapid return of fertility on stopping (within the 12-month window)

Understanding the Physiology First

Why is Breastfeeding Itself Contraceptive?

• Suppresses GnRH pulsatility
• Reduces FSH and LH
• Prevents follicular development and ovulation
• Causes lactational amenorrhoea

LAM - The Breastfeeding-as-Contraception Rule

Your notes say "6 weeks" - this needs clarification. LAM is effective for up to 6 MONTHS (not 6 weeks) if all three criteria are met. The 6-week figure refers to the postnatal review appointment, not the duration of LAM protection.

• Any supplementary feeds (formula, solids introduced)
• Baby sleeping through the night (long gaps between feeds reduce prolactin)
• Return of menstruation
• Baby > 6 months

Analysing Each Option Against the Two Goals

Option 1: Continue Breastfeeding (LAM)

• Only reliable up to 6 months postpartum
• Requires strict exclusive breastfeeding
• Once she introduces solids or supplements, or gets her period back → LAM fails → needs backup method
• Not suitable as her only method if she is already beyond 6 months postpartum or not exclusively breastfeeding

Option 2: COCP (Combined Oral Contraceptive Pill)

1. Reduced milk volume and quality - oestrogen suppresses prolactin-stimulated milk production
2. Oestrogen passes into breast milk - potential hormonal exposure to infant
3. Increased VTE risk in the postpartum period - oestrogen is thrombogenic, and postpartum is already a high-VTE state

• COCP in breastfeeding < 6 weeks postpartum = Category 4 (absolutely contraindicated)
• COCP in breastfeeding 6 weeks to 6 months = Category 3 (risks usually outweigh benefits)
• COCP in breastfeeding > 6 months = Category 2 (benefits usually outweigh risks, milk supply more established)

For this patient: COCP should NOT be used while she is still breastfeeding, regardless of timing.

Option 3: POP (Progestogen-Only Pill / Mini-Pill)

• No oestrogen - does not suppress prolactin, does not reduce milk supply
• Small amounts of progestogen pass into breast milk but are not harmful to infant
• Highly effective (~99% with perfect use)
• WHO MEC Category 1 (no restriction) from 6 weeks postpartum onward in breastfeeding women

• Primary mechanism: Thickens cervical mucus (prevents sperm penetration)
• Secondary: Suppresses ovulation (in ~50% of cycles with traditional POP; ~97% with desogestrel-containing POP like Cerazette)
• Thins endometrium

• Fertility returns within days to weeks of stopping
• No cumulative effect on future fertility
• Ideal for someone wanting to conceive in 12 months

• Irregular bleeding / spotting (most common reason for discontinuation)
• Possible amenorrhoea
• Headaches, mood changes, breast tenderness

Option 4: Depo-Provera (DMPA - Depot Medroxyprogesterone Acetate)

• DMPA is a 3-monthly injection of long-acting progestogen
• After stopping, fertility return is unpredictable and often significantly delayed
• Median time to conception after last injection: 10 months
• Range: 4 months to 2+ years
• Some women do not ovulate for up to 18-24 months after their last injection
• This is irreversible once the injection is given

Teaching point: Depo is excellent for women who want long-term contraception without daily compliance. But if any desire for pregnancy in the near future exists (within 18-24 months), Depo should be avoided.

• Reduced bone mineral density with long-term use (DEXA monitoring if >2 years)
• Irregular bleeding initially, then amenorrhoea
• Cannot be reversed once injected

Option 5: IUD (Intrauterine Device)

1. Designed for long-term contraception - inserting and removing within 12 months is poor utilisation
2. Insertion procedure - involves speculum exam and intrauterine placement; discomfort, small risk of expulsion/perforation
3. Cost-effectiveness - not appropriate for <12-month use
4. However: If the patient changes her mind or doesn't conceive, removal at any time is possible with immediate return of fertility

• Wants reliable long-term contraception (years)
• Does not plan further pregnancy for a defined long period
• Cannot take hormonal methods
• Postpartum insertion can be done at 4-6 weeks or immediately postpartum (within 48 hours)

The Answer - What to Recommend

Recommended Management:

• Continue exclusive breastfeeding → LAM provides ~98% protection
• Counsel: "The moment you introduce any formula, solids, or your period returns - you need to start contraception immediately"

• Start Progestogen-Only Pill (POP)
• Desogestrel POP (e.g., Cerazette) preferred for better efficacy and larger window
• Counsel on irregular bleeding
• When ready to conceive: simply stop the POP - fertility returns within days to weeks

Summary Concept Map

Breastfeeding woman + wants pregnancy in 12 months
                    ↓
     TWO KEY QUESTIONS:
     ① Safe in breastfeeding?
     ② Rapid return of fertility?
                    ↓
    COCP → ❌ (reduces milk supply, oestrogen)
    DEPO → ❌ (delayed fertility up to 2 years)
    IUD  → ⚠️ (safe but for long-term use)
    LAM  → ✅ (if criteria strictly met, <6 months)
    POP  → ✅ BEST ANSWER
           Safe in BF (no oestrogen)
           Fertility returns in days-weeks on stopping
           Oral, reversible, once-daily

Exam Pearl

The question tests whether you know:

1. COCP is contraindicated in breastfeeding (due to oestrogen, not progestogen)
2. Depo delays fertility and is wrong for someone wanting pregnancy within 12 months
3. IUD is long-term and not the best fit for <12-month contraception
4. POP is the correct answer - safe in breastfeeding AND has rapid fertility return
5. LAM is valid but only while strict exclusive breastfeeding criteria are met (up to 6 months - not 6 weeks)